One Health (Jun 2021)

One Health drivers of antibacterial resistance: Quantifying the relative impacts of human, animal and environmental use and transmission

  • Ross D. Booton,
  • Aronrag Meeyai,
  • Nour Alhusein,
  • Henry Buller,
  • Edward Feil,
  • Helen Lambert,
  • Skorn Mongkolsuk,
  • Emma Pitchforth,
  • Kristen K. Reyher,
  • Walasinee Sakcamduang,
  • Jutamaad Satayavivad,
  • Andrew C. Singer,
  • Luechai Sringernyuang,
  • Visanu Thamlikitkul,
  • Lucy Vass,
  • Matthew B. Avison,
  • Katherine M.E. Turner,
  • Matthew B. Avison,
  • Nour Alhusein,
  • Ross D. Booton,
  • Henry Buller,
  • Boonrat Chantong,
  • Nisanart Charoenlap,
  • Natacha Couto,
  • Punyawee Dulyayangkul,
  • Edward Feil,
  • Marjorie J. Gibbon,
  • Virginia C. Gould,
  • Helen Lambert,
  • Aronrag Meeyai,
  • Skorn Mongkolsuk,
  • Varapon Montrivade,
  • Emma Pitchforth,
  • Kornrawan Phoonsawad,
  • Nuchanart Rangkadilok,
  • Parntep Ratanakorn,
  • Kristen K. Reyher,
  • Walasinee Sakcamduang,
  • Jutamaad Satayavivad,
  • Andrew C. Singer,
  • Kwanrawee Sirikanchana,
  • Luechai Sringernyuang,
  • Tawit Suriyo,
  • Sarin Suwanpakdee,
  • Visanu Thamlikitkul,
  • Katherine M.E. Turner,
  • Lucy Vass,
  • Kantima Wichuwaranan,
  • Anuwat Wiratsudakul

Journal volume & issue
Vol. 12
p. 100220

Abstract

Read online

Objectives: Antibacterial resistance (ABR) is a major global health security threat, with a disproportionate burden on lower-and middle-income countries (LMICs). It is not understood how ‘One Health’, where human health is co-dependent on animal health and the environment, might impact the burden of ABR in LMICs. Thailand's 2017 “National Strategic Plan on Antimicrobial Resistance” (NSP-AMR) aims to reduce AMR morbidity by 50% through 20% reductions in human and 30% in animal antibacterial use (ABU). There is a need to understand the implications of such a plan within a One Health perspective. Methods: A model of ABU, gut colonisation with extended-spectrum beta-lactamase (ESBL)-producing bacteria and transmission was calibrated using estimates of the prevalence of ESBL-producing bacteria in Thailand. This model was used to project the reduction in human ABR over 20 years (2020–2040) for each One Health driver, including individual transmission rates between humans, animals and the environment, and to estimate the long-term impact of the NSP-AMR intervention. Results: The model predicts that human ABU was the most important factor in reducing the colonisation of humans with resistant bacteria (maximum 65.7–99.7% reduction). The NSP-AMR is projected to reduce human colonisation by 6.0–18.8%, with more ambitious targets (30% reductions in human ABU) increasing this to 8.5–24.9%. Conclusions: Our model provides a simple framework to explain the mechanisms underpinning ABR, suggesting that future interventions targeting the simultaneous reduction of transmission and ABU would help to control ABR more effectively in Thailand.

Keywords